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Risk Factors and Prognosis in T-Cell Posttransplantation
Lymphoproliferative Diseases: Reevaluation
of 163 Cases
Christina Tiede,1 Britta Maecker-Kolhoff,2 Christoph Klein,3 Hans Kreipe,1 and Kais Hussein1,4
Background. Posttransplantation lymphoproliferative diseases (PTLD) are mainly Epstein-Barr virus (EBV)Yassociated
disorders of B-cell origin. Due to the rarity of monomorphic T-cell PTLD (T-PTLD), knowledge about pathogenesis,
risk factors, therapy, and prognosis relies predominantly on case reports and small series. Therefore, we aimed to
provide an overview and a retrospective analysis of this rare PTLD subtype.
Methods. We analyzed all available articles on T-PTLD in the PubMed database as well as in our own databases
(Institute of Pathology/Department of Paediatric Haematology and Oncology, Hannover Medical School) from 1988
to 2010. Reevaluated parameters were gender, age, transplanted organ, immunosuppressant regimen, time between
transplantation and T-PTLD manifestation, T-PTLD subtype, virus positivity, localization, therapy, and follow-up.
Results. A total of 163 cases were evaluated. We found that hematopoietic stem cell transplantation was associated with
early-onset T-PTLD, whereas late onset occurred after immunosuppression with steroids and azathioprine without
administration of calcineurin inhibitors. The major independent favorable prognostic factors were T-PTLD of the large
granular lymphocytic leukemia subtype, young age, and a combination of radiotherapy/radiochemotherapy and re-
duced immunosuppression, whereas the hepatosplenic T-cell lymphoma subtype and cases with involvement of bone
marrow, the central nervous system, or graft had an adverse prognosis.
Conclusion. T-PTLD is a heterogeneous group of different aberrant T-cell proliferations and represents a significant
complication following transplantation, showing a uniformly poor prognosis.
Keywords: Posttransplantation lymphoproliferative disease, PTLD, T cells, T-PTLD, Risk factor, Prognosis.
(Transplantation 2013;95: 479Y488)
Transplantation medicine is based on the stratification ofthe patients’ individual risk profile, surgical techniques, intensive care, diagnostic monitoring, and drug-induced im-munosuppression (1, 2). The latter inhibits graft rejection but
also decreases the capability of the immune system to identify
aberrant cells, which promotes the development of neoplasms
after transplantation (3, 4). Posttransplantation lymphopro-
liferative diseases (PTLD), which are mainly Epstein-Barr vi-
rus (EBV)/human herpes virus-4Yassociated disorders, are
a major complication. According to the World Health Orga-
nization (WHO) classification of 2008, PTLD are subclassi-
fied into early lesions (indistinguishable from lymphocytic
hyperplasia or infectious mononucleosis), polymorphic
PTLD (lymphocytic proliferation with histoarchitectural
effacement but no lymphoma), and malignant lymphoma
resembling monomorphic B- or T-cell PTLD and Hodgkin’s-
type PTLD (5). In contrast to the more than 90% of adult
patients who are latently EBV positive, pediatric and juvenile
patients are more often EBV naBve before transplantation
and have their primary infection under immunosuppres-
sive therapy, which puts them at a fourfold higher risk
for PTLD manifestation (3, 4). The pathogenesis is based
on the immunosuppression-associated reduction of CD8+
T cells, resulting in an imbalance of EBV-positive B cells,
virus-specific cytotoxic T cells, and regulatory T cells, which
permits the EBV-positive B-cell population to proliferate and
generate a PTLD phenotype (3, 4). Due to the EBV-associated
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pathomechanism, monomorphic PTLD are predominantly
disorders of B lineage (B-PTLD), mainly high-grade B-cell
non-Hodgkin’s lymphomas.
The rarest forms of monomorphic PTLD are Hodgkin’s
lymphomas and PTLD of T lineage (T-PTLD). T cells do
not usually express EBV receptor CD21; therefore, in most
cases, the pathogenesis of monomorphic T-PTLD might
not be based on EBV infection alone (3, 4). Due to the rarity
of T-PTLD, prospective studies with large numbers of
patients are not applicable and knowledge about risk fac-
tors, therapy, and prognosis relies predominantly on case
reports and small series. Therefore, we aimed to provide a
retrospective analysis of the rare monomorphic T-PTLD
subtype to provide more general insights into this disease.
RESULTS




Our own PTLD database comprises 117 monomorphic
PTLD: 6 T-PTLD, 104 B-PTLD (80 diffuse large B-cell lym-
phomas, 10 Burkitt’s lymphomas, and 14 other B-cell and
plasma cell neoplasms), and 7 Hodgkin’s PTLD. Therefore,
in our cohort, the frequency of T-PTLD among all mono-
morphic PTLD is 5% (n=6 of 117).
We identified a total of 163 T-PTLD: 157 cases from
the literature, for whom primary data were published, and
the 6 cases in our own files. Our own cases comprise three
children and three adults (Fig. 1; Tables 1 and 2). T-PTLD
phenotypes were hepatosplenic T-cell lymphoma (HSTCL),
peripheral T-cell lymphoma, not otherwise specified (PTCL,
NOS), cutaneous T-cell lymphoma (CTCL; including my-
cosis fungoides, Sézary syndrome, primary cutaneous T-cell
lymphoma, and subcutaneous panniculitis-like T-cell lym-
phoma), anaplastic large cell lymphoma (ALCL), adult T-cell
leukemia/lymphoma (ATL), T-cell large granular lympho-
cytic leukemia (LGL), PTLD with natural killer cell pheno-
type, and T-PTLD with manifestation in the central nervous
system. Approximately half of T-PTLD was either CD4+
(n=32 of 60 [53%]) or CD8+ (n=28 of 60 [47%]); full
immunoprofile was not reported in all cases.
Among Patients With T-Cell Posttransplantation
Lymphoproliferative Disease, Kidney
Recipients Are Common
In patients in whom T-PTLD manifested, the most
frequently transplanted organs were kidneys (n=107) (6Y78,
including two cases with additional pancreas transplantation
(Table 2) (27, 67). In one case, the kidney transplant failed
(70). Four patients had been retransplanted (27, 51).
Other solid organ transplants were heart (n=26) (57,
71, 73, 79Y94), including one patient who received a liver
transplant 4 months after heart transplantation and devel-
oped T-PTLD 5 months afterward (87); liver (n=17)
(95Y105); lung (n=3) (105Y107), including one heart-lung
(107); and multivisceral organ transplantation (n=1) (108).
Hematopoietic stem cell transplantation comprised bone
marrowYderived cells (n=6) (109Y111), autologous periph-
eral bloodYderived cells (n=2) (112, 113), and blood-derived
cells after failed bone marrow transplantation (n=1) (114).
Epstein-Barr Virus Is Present in Approximately
One-Third of T-Cell Posttransplantation
Lymphoproliferative Diseases
T-PTLDYYassociated viruses were EBV, cytomegalovirus/
human herpes virus-5 (CMV), human T-cell leukemia vi-
rus (HTLV), and human herpes virus-6 (HHV-6), includ-
ing coinfections with EBV/CMV and EBV/HTLV (see
Tables S1 and S2, SDC, http://links.lww.com/TP/A735).
EBV status was reported in 126 T-PTLD cases: 46 of 126
(36.5%) were EBV-positive (none of our own cases were
EBV-positive).
EBV was demonstrated in 41 of 46 tumor samples
(8, 11, 15, 17Y19, 28, 35, 38, 39, 41, 44, 47, 48, 55, 58, 62, 63,
67, 73, 77, 81, 88, 91, 92, 94, 97, 99, 100, 103, 112, 113),
whereas, in 5 of 46 cases, only EBV seropositivity was present
(12, 23, 89, 90, 102). In two of these five seropositive cases,
no biopsy was performed (90, 102). Whereas, in two seropo-
sitive cases, the neoplastic cells were stated to be EBV-negative
(23, 89), the presence of EBV-positive tumor cells was not
reported in one seropositive case (102). Comparison of EBV-
positive and EBV-negative cases (independent of coinfec-
tions) revealed no significant difference regarding the time
between transplantation and T-PTLD manifestation (P=0.9)
as well as no significant prognostic impact regarding sur-
vival (P=0.6), even if only cases with EBV-positive tumor cells
were considered and EBV-seropositive cases were excluded.
The only T-PTLD subtype that was associated with a
particular virus was ATL. HTLV was positive (mainly se-
ropositive) in seven of eight ATL-PTLD cases (28, 29, 31,
68, 70, 83); however, this virus was not systematically
tested in most other cases (see Tables S1 and S2, SDC,
http://links.lww.com/TP/A735).
Risk Factors for T-Cell Posttransplantation
Lymphoproliferative Disease Manifestation:
Hematopoietic Stem Cell Transplantation and
Calcineurin Inhibitors
The earliest T-PTLD manifestation (early-onset PTLD
G12 months) was found after hematopoietic stem cell trans-
plantation (median, 5 months; range, 2Y43 months), which
was, according to Bonferroni-adjusted bivariate analysis, sig-
nificantly earlier than after kidney (1Y324 months) (82), heart
(9Y168 months) (70), or liver (2Y180 months) (46) trans-
plantation (Fig. 2A). Multivariate analysis confirmed these
significant results for hematopoietic stem cell versus kidney,
heart, and liver transplantation (PG0.05) and also showed a
significant difference regarding underlying lung/heart-lung
transplantation (32Y108 months; P=0.0135 versus hemato-
poietic stem cell transplantation) (64). In one case, T-PTLD
manifested 24 months after multivisceral organ transplanta-
tion (108), which was comparable with the time period be-
tween single-organ transplantation and disease manifestation.
T-PTLD manifestation-associated immunosuppres-
sive drugs/drug combinations were evaluated (Fig. 2B).
Bonferroni-adjusted bivariate analysis and multivariate
analysis showed that T-PTLD developed earlier in patients
who received tacrolimus (alone or with other drugs) than in
patients with azathioprine therapy (alone or with other
drugs, except cyclosporine A or tacrolimus; PG0.0001).
Pediatric/juvenile T-PTLD comprised only 13% of all
T-PTLD (n=21 of 163; n=3 of 21 in our own cases) (8, 71,
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FIGURE 1. Variable histopathology of T-PTLD. A, patient #2 (see Table 1, PTCL, NOS): liver graft showed portal infiltration
by CD3+/CD4+ small cells (CD4 is depicted; original magnification, 25). In addition, an abdominal lymph node showed a
similar infiltration (not depicted). Bone marrow was not involved. B, patient #4 (PTCL, NOS): specimen of the lung showed
infiltration by blastoid, mainly moderately enlarged CD3+/CD8+ cells that revealed coexpression of granzyme B and TIA1
(Giemsa, 400). C, patient #5 (PTCL, NOS): bone marrow showed interstitial and nodular infiltration by CD3+/CD4+ cells
(CD3 is depicted; 25) that partially coexpressed granzyme B and TIA1. Nonlymphoid hematopoiesis showed moderate
hyperplasia. D, most cells were small, some were slightly enlarged, and nuclei showed dense chromatin (Giemsa,400). E,
patient #6 (mycosis fungoides with unusual involvement of the pharynx): palmar skin specimen is depicted and shows
dense epidermotropic and partially intraepithelial lymphoid infiltration (Giemsa,25). The small cells were predominantly
CD3+/CD4+ and very few larger cells were CD30+. F, similar atypical T-cell infiltrates were found in larynx tissue specimen
(CD4 is depicted; 100). PTCL, NOS, peripheral T-cell lymphoma, not otherwise specified; T-PTLD, T-cell post-
transplantation lymphoproliferative diseases.

















#1 Heart F G0.5 NA ALCL Lymph node 12 (dead)
#2 Liver M 0.5 20 PTCL, NOS Graft, lymph node 1 (dead)
#3 Liver M 1 2 PTCL, NOS Lymph node, pleural
fluid
48 (alive)
#4 Kidney M 30 312 PTCL, NOS Lung NA
#5 Kidney M 43 96 PTCL, NOS Bone marrow NA
#6 Liver M 53 21 Mycosis fungoides Skin, larynx 29 (alive)
ALCL, anaplastic large cell lymphoma; NA, not available; PTCL, NOS, peripheral T-cell lymphoma, not otherwise specified; T-PTLD, T-cell post-
transplantation lymphoproliferative diseases.
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73, 79, 81, 85, 91, 93, 95, 99, 100, 104, 105, 108, 114). Age less
than 18 years (n=21; median, 12 years; range, G0.5Y16 years)
or age more than 60 years (n=18; median, 68.5 years; range,
61Y75 years) (6, 12, 15, 21, 35, 44, 54, 55, 70, 74, 83, 87, 88,
90, 92, 96, 101) were not general risk factors.
Hepatosplenic T-Cell
LymphomaYPosttransplantation
Lymphoproliferative Disease Has an
Adverse Prognosis
In the bivariate (but not multivariate) analysis, juve-
nile patients had a significantly better survival than adult
patients (Fig. 3A), and with regard to PTLD subtypes, the
best prognosis was found for the LGL type (18 months
median follow-up; range, 4Y36 months; survival data from
7 of 8 cases, 6 of 7 alive in the follow-up period) (21, 45,
109, 110). Regarding this, patients with LGL-PTLD were
all adults (median age, 48 years; range, 36Y70 years); none
of the pediatric/juvenile patients had an LGL-PTLD but
PTCL, NOS (n=12; n=2 of 12 in our own cases) (71, 73, 79,
81, 99, 100, 104, 105, 108), ALCL (n=7; n=1 of 7 in our own
cases) (8, 71, 81, 91, 93, 114), and CTCL (n=2) (85, 95).
Patients with CD4+ or CD8+ T-PTLD had a similar
survival (P=0.4).
HSTCL-type PTLD had an adverse prognosis (4
months median survival; range, 0.5Y12 months; n=19, all
died during the follow-up period; Fig. 3B) and showed a
significantly lower overall survival versus CTCL (bivariate
and multivariate analysis) and LGL (only in bivariate but
not multivariate analysis) (10, 18, 33, 35, 42, 55, 58, 59, 64,
76, 83, 102).
In general and independent of the T-PTLD subtype,
infiltration of the central nervous system (n=5) (22, 65, 67, 70,
96), bone marrow (n=24 nonhematopoietic stem cell trans-
planted cases; n=1 of 24 in our own cases) (6, 10, 18, 27, 34, 39,
64, 76, 83, 84, 93, 98, 102, 104, 105), and graft (kidney [n=6]
(12, 37, 55, 69, 71, 77), liver [n=5; n=1 of 5 in our own cases]
(102, 103, 105), hematopoietic stem cells [n=3] (109, 110),
and multivisceral [n=1] (108)) was associated with a poor
prognosis (significant in Bonferroni-adjusted bivariate anal-
ysis but not multivariate analysis; Fig. 3C).
Basis of Therapy: Reduced Immunosuppression
Therapy regimens were variable and were mainly
based on radiotherapy and chemotherapy, corticosteroid
administration, and reduction of immunosuppressants.
Treatment protocol alterations (e.g., due to rescue efforts)
were included. Chemotherapy and radiochemotherapy had
been performed in 48 cases and immunosuppression (with
or without cytoreductive therapy) had been reduced in
56 patients. Fifteen of 56 patients were treated solely with
reduced immunosuppression (no additional therapy): 6 of
15 (40%) died after a median period of 2.5 months, whereas
9 of 15 (60%) were alive after a median of 13 months. Che-
motherapy alone appears to be less efficient than other
therapy strategies (e.g., reduced immunosuppression alone),
but, in general, there was no significant difference (Fig. 3D).
Eleven patients received no therapy (6, 7, 15, 27, 28, 35, 55,
71, 83, 101) mainly because of rapid progression or due to
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complications after a median of 3 weeks. As could be expected,
these cases had a significantly low overall survival rate (PG0.05,
bivariate and multivariate analyses).
DISCUSSION
Monomorphic B-PTLD mainly comprises two types of
high-grade lymphomas: diffuse large B-cell lymphoma and
Burkitt’s lymphoma (2Y5, 115). In contrast, T-PTLD manifest
in a variety of aberrant T-cell proliferations. The pathogenesis
of B-PTLD is mostly based on virus-infected B lymphocytes.
Although it is generally appreciated that T lymphocytes do
not express the EBV receptor CD21, some T-PTLD might
show aberrant T cells, which are positive for CD21 and EBV
(58). CD21 was not tested in most cases and only one-third of
T-PTLD reevaluated in this study were positive for EBV. In
contrast, B-PTLD are more frequently associated with EBV
(970%) (3, 4, 115). Although children are at a fourfold higher
risk to develop a PTLD because they are more frequently
EBV-naBve at the time of transplantation (3), the rarity of
T-PTLD in young patients had been recognized earlier (105).
In this review of a large number of cases, 13% pediatric/
juvenile T-PTLD were identified; young age was associated
with a better survival. Other detectable viruses were CMV (8,
17, 21, 47, 80, 99Y101, 109, 110), HTLV (28, 29, 31, 68, 70, 83),
and HHV-6 (42). Some T-PTLD patients were even coin-
fected with EBV and CMV (8, 17, 47, 99, 100) or EBV and
HTLV (28), whereas coinfection of tumor cells has not been
shown in these cases (non-EBV viruses were mainly detectable
in the serum but have not been systematically analyzed in
tumor samples). Virus seropositivity, however, might be as-
sociated with immunosuppression rather than necessarily
being the initiating cause in all T-PTLD; for example, in
two EBV-seropositive patients, the PTCL tumor cells were
EBV-negative (23, 89). Overt primary immune disorders
are, similar to PTLD, frequently associated with EBV-positive
B-cell lymphomas but rarely with T-cell lymphomas (5).
Furthermore, in nontransplanted immunocompetent patients,
high-grade lymphomas are more frequently of B rather than of
T lineage, indicating a different predisposition of these two
lymphocytic differentiations to generate an aberrant clonal
proliferation. However, the molecular basis of monomorphic
PTLD is partially different from sporadic malignant lympho-
mas, as could be demonstrated by gene expression profiling
(116). The relatively long latency between transplantation and
T-PTLD onset may be explained by molecular events:
FIGURE 2. Predisposing risk factors in T-PTLDpatients. For furtherdetails, seeTable S3 (SDC, http://links.lww.com/TP/A735).
Aza, azathioprine; CsA, cyclosporine A; HSC, hematopoietic stem cells; IS, immunosuppression; T-PTLD, T-cell post-
transplantation lymphoproliferative diseases; Tx, transplant.
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whereas EBV infection and transformation is an early event
after transplantation, typical molecular alterations such as ALK
translocations in ALCL may occur later. In our reevaluation, we
found that ALK status was documented only in a small sub-
fraction of T-PTLD. Three cases were ALK-positive (87, 93, 96),
whereas five ALCL were ALK-negative (8, 55, 78, 91, 101).
FIGURE 3. Prognostic factors in T-PTLD patients. For further details, see Table S4 (SDC, http://links.lww.com/TP/A735).
ALCL, anaplastic large cell lymphoma; ATL, adult T-cell leukemia/lymphoma; chemo, chemotherapy; Chemo/Chemo+RI,
chemotherapy alone and chemotherapy with immunosuppression; CNS, T-PTLD with manifestation in the central nervous
system; CNS/BM/graft, T-PTLD with infiltration of the central nervous system, bone marrow, and graft; CTCL, cutaneous
T-cell lymphoma (including mycosis fungoides, Sézary syndrome, primary cutaneous T-cell lymphoma, and subcutaneous
panniculitis-like T-cell lymphoma); HSTCL, hepatosplenic T-cell lymphoma; LGL, T-cell large granular lymphocytic leukemia;
NK, PTLD with natural killer cell phenotype; nodal+extranodal, lymph node infiltration without documented other extranodal
involvement and extranodal infiltration, except bone marrow, the central nervous system, or graft showed similar overall
survival and were therefore combined; PTCL, NOS, peripheral T-cell lymphoma, not otherwise specified; Radio, radiotherapy;
Radio/Radio+RI, radiotherapy alone and radiotherapy with immunosuppression; Radio+Chemo/Radio+Chemo+RI, radio-
chemotherapy and radio-chemotherapy with immunosuppression showed no significant difference and were therefore
combined; RI, reduced immunosuppression alone; T-PTLD, T-cell posttransplantation lymphoproliferative diseases.
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Furthermore, in this small number of cases, the ALK status
showed no significant prognostic impact.
We found that immunosuppressive regimens with
azathioprine but without administration of calcineurin inhi-
bitors were associated with a later manifestation of T-PTLD
(dose-dependent associations could not be performed). In
contrast, calcineurin inhibitors, particularly tacrolimus and
to a lesser extent cyclosporine A, were associated with early-
onset T-PTLD. This does not imply that calcineurin inhi-
bitors generally increase the risk to develop T-PTLD but
only that the disease manifests earlier among T-PTLD
patients. Combinations other than steroids and azathio-
prine without calcineurin inhibitors were too heteroge-
neous to draw a meaningful conclusion, although these
patients showed the earliest T-PTLD manifestation.
Similar to B-PTLD, the transplant organ with the
highest number of monomorphic T-PTLD is the kidney (3).
However, it must be taken into account that kidney trans-
plantation is more frequently performed than any other
organ transplantation. PTLD can manifest as early as a few
weeks after transplantation but, as could be demonstrated for
B-PTLD, early-onset PTLD are not associated with a specific
organ (117). We found that hematopoietic stem cell trans-
plantation was a predisposing risk factor for the development
of early-onset T-PTLD. The reason might be that, in these
patients, a subfraction of defective endogenic hematopoietic
stem cells remained after transplantation or even that the
donor’s hematopoietic stem cells have occult defects and that
this aberrant reservoir generates the early-onset PTLD (109,
118). Alternatively, late PTLD may not occur in hematopoi-
etic stem cells recipients, because immunosuppressive medi-
cation is usually tapered and immunocompetence normalizes
over time in this patient population. Because of the large
number of donor periportal lymphocytes, liver transplants are
thought to be more often associated with donor-derived
PTLD, mainly polymorphic PTLD, whereas monomorphic
B-PTLD are more often recipient derived (117, 119).
We and others could previously show that infiltration
of bone marrow, the central nervous system, and graft is an
unfavorable prognostic factor in B-PTLD (120, 121). The
HSTCL subtype and infiltration of these organ sites were
also associated with a poor prognosis in T-PTLD. Favorable
prognostic factors were young age and LGL-PTLD. None of
the young patients had LGL-PTLD, indicating two inde-
pendent factors.
An effective therapy for T-PTLD must account for the
individual’s age, constitution, and compliance (3). There-
fore, it is difficult to suggest an optimal protocol for the
treatment of heterogeneous T-PTLD subtypes based on ret-
rospective data from multiple hospitals with different treat-
ment modalities. Reduction of immunosuppression is
usually the first measure if PTLD occurs. Patients receiving
no further treatment will represent either the best (‘‘cured’’)
or the worst (‘‘no other treatment tolerable’’) prognostic
group. In our analysis, most patients with reduced immu-
nosuppression survived. In contrast to B-PTLD, where
monoclonal antibody treatment has become a well-tolerated
standard of care during the last decade, T-PTLD usually
requires intensive chemotherapy and radiotherapy treat-
ment. Our analysis indicates that, similar to de novo
malignancies, patients with T-PTLD may benefit from
addition of radiotherapy to chemotherapy and, similar to
B-PTLD, reduction of immunosuppression. A prospective
study is, of course, mandatory to verify these retrospective
results. To the best of our knowledge, due to the rarity of
T-PTLD, no such prospective study has yet been conducted.
However, we could provide the first evaluation of a large
number of T-PTLD.
There are several previously described issues in this
current evaluation, but it has to be taken into account that
until now our knowledge on rare T-PTLD has been based
mainly on findings derived from single case reports that
have not been systematically compared with other case
reports or extrapolation/transmission of B-PTLDYderived
findings to T-PTLD. The impact of this analysis is not
simply reporting additional cases of T-PTLD, but we aimed
to provide a clinically relevant general overview on this rare
PTLD subtype. In summary, T-PTLD is a heterogeneous
group of different aberrant T-cell proliferations and repre-
sents a significant complication following transplantation,
showing a uniformly poor prognosis. Unfavorable prog-
nostic factors are the HSTCL subtype and involvement
of bone marrow, the central nervous system, and graft.
Hematopoietic stem cell transplantation is associated with
early-onset T-PTLD, whereas a late onset was found after
immunosuppression with azathioprine without administra-
tion of calcineurin inhibitors. The major independent favor-
able prognostic factors are LGL-PTLD, young age at diagnosis,




According to the WHO classification, T-PTLD is defined as a mono-
morphic lesion that comprises all T-cell lymphomas as well as natural killer
cell lymphomas, which can be found in nontransplanted patients (5).
We searched for all available articles on T-PTLD in the PubMed da-
tabase using the keywords posttransplantation lymphoproliferative dis-
ease, PTLD, T cell, and T-PTLD as well as in our own databases (Institute
of Pathology/Department of Paediatric Haematology and Oncology,
Hannover Medical School) for the time period between 1988 and 2010.
The local ethics committee has approved the retrospective evaluation of
our archived files and tissue samples that have been taken during the
routine diagnostic procedure (formalin-fixed and paraffin-embedded
samples; registration code #911-2011).
PTLD not fulfilling the WHO criteria for T-PTLD (5) were excluded
(‘‘polymorphic T-PTLD’’) (115, 122).
The following parameters were reevaluated: gender, age, transplanted
organ, immunosuppressant regimen, time between transplantation and
T-PTLD manifestation, T-PTLD subtype, virus positivity, localization,
therapy after T-PTLD diagnosis, and follow-up.
To determine the frequency of T-PTLD, we used our own PTLD data-
bases (Institute of Pathology/Department of Paediatric Haematology and
Oncology, Hannover Medical School), which comprise early lesions
(n=79), polymorphic PTLD (n=21), and monomorphic PTLD (n=117).
Statistical Analysis
All available data were statistically analyzed with Prism 5.0 (GraphPad
Software, San Diego, CA) and SAS 9.3 (SAS Institute, Cary, NC). Kaplan-
Meier analysis was used for survival analysis and calculation of the
corresponding hazard ratio was performed with Prism. Log-rank/Mantel-
Cox test and, for bivariate analysis, two-tailed t test/Mann-Whitney test
with Bonferroni adjustment of P values were used for analysis of signifi-
cance (Prism). Multivariate analysis was performed with the Breslow
method for ties (SAS). For risk factor analysis associated with T-PTLD
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manifestation, the time of transplantation until first diagnosis of T-PTLD
and, for survival analysis, the time of T-PTLD manifestation until last
follow-up date was evaluated.
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